Epidemiology and Metabolomics of Patients with Glucocorticoid-induced Diabetes Mellitus in the DD2 Cohort – A nationwide case-control study

Abstract

Introduction: Glucocorticoid-induced diabetes mellitus (GIDM) is a known and potential severe side-effect of glucocorticoid treatment. However, there is a lack of knowledge concerning prevalence, risk factors, prevention and treatment leading to insufficient evidence-based care.

Aims: To systematically compare patients with type 2 diabetes (DM2) and GIDM to gain insight into differences in epidemiology and risk factors as well as analyze the metabolome of the two groups to improve the understanding of GIDM.

Methods: Patients from the DD2 cohort who have GIDM will be compared with a control group of DD2 patients with DM2. The metabolic profiles of the two cohorts will be compared and the GIDM diagnosis will be validated by confirming the ICD-10 codes with information from the patient’s journals if possible.

Results: Validation and identifying specific risk factors for GIDM as well as validation of previously collected metabolomics data about GIDM patients. Potentially showing associations between certain metabolites and risk of GIDM.

Formål

1. To compare GIDM patients and a DM2 control group regarding observed clinical and demographic information as well as metabolomic data

2. To validate the GIDM diagnosis in the DD2 cohort by accessing the patient journal up to 1 year prior to the registered diagnosis of GIDM (SKS code based on ICD-10).

3. To perform metabolomics on biobank material from the DD2 cohort – in the complete GIDM cohort and a randomly selected DM2 cohort.

4. Validate data from previous metabolomics research on a GIDM cohort with the DD2 GIDM cohort.

Studiepopulation

Patients with GIDM will be selected from the DD2 database and the inclusion criterium will be any DE13.X SKS code and recording of a redeemed prescription for oral steroid therapy in the past 6 months up to inclusion in the DD2 cohort. The exclusion criteria are a double diagnosis of DM2 and GIDM and missing data. The control group will be selected randomly from the DD2 database. Exclusion criteria are missing data and missing biobank material for metabolomic analysis.